Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier:
NCT01063257
First received: February 3, 2010
Last updated: March 18, 2014
Last verified: March 2013
  Purpose

This study aims to determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs) of low dose IV clofarabine for MDS patients after treatment failure of azacitidine.


Condition Intervention Phase
Myelodysplastic Syndrome
Drug: Clofarabine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Multicenter Study of IV Clofarabine in Patients With High-Risk Myelodysplastic Syndrome Who Have Failed Therapy With Azacitidine: the NIDEVOL Study

Resource links provided by NLM:


Further study details as provided by Groupe Francophone des Myelodysplasies:

Primary Outcome Measures:
  • To determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs) [ Time Frame: 1-2 months ] [ Designated as safety issue: Yes ]
    After one course treatment.


Secondary Outcome Measures:
  • To determine response rates. [ Time Frame: 1-16 months. ] [ Designated as safety issue: No ]
    After one, two and eight courses of treatment.

  • To evaluate the response duration. [ Time Frame: 1-16 months ] [ Designated as safety issue: No ]
    After one, two and eight courses of treatment.

  • To evaluate time to IPSS progression. [ Time Frame: 1-16 months ] [ Designated as safety issue: No ]
    After one, two and eight courses of treatment.

  • To evaluate loss of RBC transfusion independence and hospitalization duration. [ Time Frame: 1-16 months ] [ Designated as safety issue: No ]
    After one, two and eight courses of treatment.

  • To evaluate rates of rehospitalization for non-hematological toxicities, severe bleeding or febrile neutropenia. [ Time Frame: 1-16 months ] [ Designated as safety issue: No ]
    After one, two and eight courses of treatment.


Enrollment: 76
Study Start Date: April 2010
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A
Clofarabine treatment at D1-D5
Drug: Clofarabine

The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:

DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).

The DLa will be the following:

DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation.

Other Name: EVOLTRA®
Experimental: Cohort B
Clofarabine treatment at D1, D3, D5, D8, D10
Drug: Clofarabine

The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:

DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).

The DLa will be the following:

DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation.

Other Name: EVOLTRA®

Detailed Description:

The study is an open-label, 3+3 dose-escalation, phase I/II study.The duration of enrollment in the phase I study is 12 months.

Fourteen patients will be enrolled at the RD using the selected dosing in each cohort, for an enrollment period of 12 months.

Each patient may receive up to 8 courses, every 4 to 8 weeks in a D1-D5 schedule or every other day from D1 to D10.

Each patient will be followed for up to 24 months.

Primary endpoint of the phase I part:

  • To determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs) of increased doses of IV clofarabine administered either daily from D1 to D5 for a 28 to 56 day-course or every other day from D1 to D10 for a 28 to 56 day-course.

Secondary endpoints:

  • To determine response rates, as defined by the 2006 modified IWG criteria, associated with the two different dosing and scheduling of clofarabine in patients with high-risk MDS or AML patients with less than 30% marrow blasts (RAEB-T in FAB MDS classification), previously treated by azacitidine and without erythroid response after 6 cycles of azacitidine.
  • To evaluate response duration, time to IPSS progression, and loss of RBC transfusion independence in these patients.
  • To evaluate hospitalization duration, rates of rehospitalization for non-hematological toxicities, severe bleeding or febrile neutropenia.

If treatment is feasible the study will be extended to the phase II part.

Study Objectives:

Primary endpoint:

  • To confirm safety and hematological toxicity in 14 additional patients. Secondary endpoints
  • To evaluate response duration, time to IPSS progression, and loss of RBC transfusion independence in these patients.
  • To evaluate hospitalization duration, rates of rehospitalization for non hematological toxicities, severe bleeding or febrile neutropenia.
  • To determine the response rate as defined by the 2006 modified IWG criteria.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 18 years or more with MDS according to FAB classification and intermediate-2 or high IPSS risk scores, or CMML (with WBC < 13 x 109/L and bone marrow blasts > 10 %) according to WHO classification, or AML according to WHO classification if less than 30 % bone marrow blasts (RAEB-T according to FAB MDS classification or AML according to WHO classification with more than 30 % with bone marrow blasts only if preceded by a proven MDS phase.
  • Patients previously treated by azacitidine (Vidaza®) in proven progression, or stable after 6 courses with ongoing transfusion dependent anemia (> 4 RBC units in the 8 weeks preceding inclusion (as erythroid response in IWG 2006 criteria is reduction of at least 4 RBC units in 8 weeks).
  • Previous biological and or targeted therapies of MDS or AML are allowed if stopped more than 1 month before inclusion.
  • ECOG PS ≤ 2.
  • Adequate renal and liver function :

    i.e. Serum creatinine < 110 microM in men or 90 microM in women. If plasma creatinine level < 90 - 110 microM, then the estimated glomerular filtration rate (GFR) must be < 50 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation where Predicted GFR (mL/min/1.73 m2) = 32788 x (plasma creatinine level (microM)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is African American)

  • Bilirubin < 1.5 x ULN, (except increased unconjugated bilirubin due to dyserythropoiesis).
  • Aspartate transaminase (AST)/alanine transaminase (ALT) < 2.5 × ULN and Alkaline phosphatase < 2.5 × ULN.
  • Absence of pregnancy or lactation in female patients (Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment).
  • Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
  • Provided signed written informed consent.
  • Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

Exclusion Criteria:

  • Patients with AML and bone marrow blasts count of 20-30%, if candidates to intensive AML type chemotherapy.
  • Known hypersensitivity to clofarabine or excipients.
  • Concomitant malignant disease.
  • Active uncontrolled infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
  • Concomitant severe cardiovascular disease, i.e. congestive heart failure (NYHA grade > 3).
  • Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
  • No affiliation to a national insurance scheme directly or to an equivalent system.
  • Chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
  • Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicities from any previous therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01063257

Locations
France
Hôpital Avicenne
Bobigny, France, 93009
Institut Paoli-Calmettes
Marseille, France, 13009
Hôpital Saint-Louis
Paris, France, 75475
Hopital Cochin Service d'Hématologie
Paris, France, 75679
Centre Henri Becquerel
Rouen, France, 76038
Sponsors and Collaborators
Groupe Francophone des Myelodysplasies
Genzyme, a Sanofi Company
Investigators
Principal Investigator: Thorsten Braun, MD Groupe Francophone des Myélodysplasies
Study Chair: Claude Gardin, MD Groupe Francophone des Myélodysplasies
  More Information

Additional Information:
No publications provided

Responsible Party: Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier: NCT01063257     History of Changes
Other Study ID Numbers: GFM-CLO-08
Study First Received: February 3, 2010
Last Updated: March 18, 2014
Health Authority: France: ANSM agence nationale de sécurité du médicament et des produits de santé

Keywords provided by Groupe Francophone des Myelodysplasies:
Myelodysplastic Syndrome

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Syndrome
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Disease
Pathologic Processes
Clofarabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 29, 2014